The Impact of II-look Ureteroscopy on Survival in Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Study of EAU-YAU Urothelial Working Group

Background and objective: No previous study quantified the survival outcomes of second-look ureteroscopy (SU). We hypothesized that patients who underwent SU might exhibit better survival outcomes than their no-SU counterparts. Methods: We relied on a multicenter retrospective database including 358 patients with UTUC treated conservatively between 2010 and 2021. Endpoints, namely overall survival (OS) and radical nephroureterectomy (RNU) rates, modeled as competing event for other-cause mortality (OCM), were quantified. Cancer-specific mortality (CSM), and OCM were also quantified according to SU. Inverse probability of treatment weighting (IPTW) methodology was used to assess OS. Landmark analysis for OS at 2 mo was also performed. Key findings: 0.02). Within tumor ≤10 mm, four (3%) UTUC recurred in the first 9 mo of follow-up. Conclusions and clinical implications: Within the current study, SU ensured an optimal clinical decision-making. Specifically, CSM and OCM rates of SU patients and their counterparts not receiving SU validated the patients with UTUC selection for conservative treatment.

Authors

Institutions

Publication Details

Journal
European Urology Open Science
Published
2026-04-27
DOI
https://doi.org/10.1016/j.euros.2026.03.008
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Impact of II-look Ureteroscopy on Survival in Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Study of EAU-YAU Urothelial Working Group

Alberto Breda, Francesco Di Bello, Angelo Territo, P. Beltrami et al.
European Urology Open Science
Bladder and Urothelial Cancer Treatments
article

The Impact of II-look Ureteroscopy on Survival in Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Study of EAU-YAU Urothelial Working Group

Alberto Breda, Francesco Di Bello, Angelo Territo, P. Beltrami, Andrea Gallioli, Ekaterina Laukhtina, Micheal Baboudjian, Lucia Dieguez, Andrea Mari, Marco Moschini, Francesco Soria, David D’Andrea, Gautier Marcq, Francesco Gabriele Celso, Joan Palou, Francesco Del Giudice, Benjamin Pradere, Paula Izquierdo, José Daniel Subiela, Wojciech Krajewski, Giuseppe Basile, Luca Afferi, Giulio Avesani, Elisa De Lorenzis
article en

Abstract

Background and objective: No previous study quantified the survival outcomes of second-look ureteroscopy (SU). We hypothesized that patients who underwent SU might exhibit better survival outcomes than their no-SU counterparts. Methods: We relied on a multicenter retrospective database including 358 patients with UTUC treated conservatively between 2010 and 2021. Endpoints, namely overall survival (OS) and radical nephroureterectomy (RNU) rates, modeled as competing event for other-cause mortality (OCM), were quantified. Cancer-specific mortality (CSM), and OCM were also quantified according to SU. Inverse probability of treatment weighting (IPTW) methodology was used to assess OS. Landmark analysis for OS at 2 mo was also performed. Key findings: 0.02). Within tumor ≤10 mm, four (3%) UTUC recurred in the first 9 mo of follow-up. Conclusions and clinical implications: Within the current study, SU ensured an optimal clinical decision-making. Specifically, CSM and OCM rates of SU patients and their counterparts not receiving SU validated the patients with UTUC selection for conservative treatment.

European Urology Open ScienceVol. 88
Universitat Autònoma de Barcelona (ES), University of Padua (IT), Vita-Salute San Raffaele University (IT), University of Milan (IT), Universidad de Alcalá (ES), Policlinico Umberto I (IT), Hospital de Sant Pau (ES), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Wroclaw Medical University (PL), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), Ospedale Maggiore (IT), Assistance Publique Hôpitaux de Marseille (FR), Comprehensive Cancer Center Vienna (AT), Azienda Ospedaliero-Universitaria Careggi (IT), Luzerner Kantonsspital (CH), IRCCS Ospedale San Raffaele (IT), Puigvert Foundation (ES), Hôpital Claude Huriez (FR), Kantonsspital Aarau (CH), Hospital Universitario Ramón y Cajal (ES), Yves Rocher (France) (FR), Institut de Recerca Sant Pau (ES), University of Florence (IT), University of Naples Federico II (IT), Medical University of Vienna (AT), Sapienza University of Rome (IT)
Openalex Percentile: Top 20%
Bladder and Urothelial Cancer Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.